我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
55
16 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1858
进行中（未招募）
3
5.5%
已完成
15
27.3%
尚未招募
13
23.6%
招募中
14
25.4%
终止
4
7.3%
Unknown
撤回
暂无批准数据
- Glucotrack has received ethical approval from St. Vincent's Hospital Melbourne HREC for a year-long clinical study of its implantable continuous blood glucose monitor in patients with type 1 and type 2 diabetes. - The multi-center study will enroll up to 30 participants requiring intensive insulin therapy, with first implantations expected by July 2025 and potential extension to three years of monitoring. - Unlike traditional CGMs that measure glucose in interstitial fluid, Glucotrack's device directly measures blood glucose with no wearable component and is designed to function for up to three years.
